Pharmaceutical intermediates
Elinzanetant Intermediates
9 pharmaceutical intermediates for Elinzanetant. Indication: Hot flashes; breast cancer; vasomotor syndrome; menopausal symptoms.
About Elinzanetant
- Originator
- GlaxoSmithKline (GSK)
- Indication
- Hot flashes; breast cancer; vasomotor syndrome; menopausal symptoms
- Approved Date
- 07/10/2025
- NCE Patent
- 10/24/2030
- DS/DP
- 09/15/2026
Available intermediates
9 intermediates currently listed for Elinzanetant. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| N-Boc-O-Benzyl-D-serine | 47173-80-8 | / | / |
| 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine hydrochloride | 2642577-31-7 | / | / |
| N-[6-Chloro-4-(4-fluoro-2-methylp henyl)-3-pyridinyl]-N,a,a-trimethy | 825643-73-0 | / | / |
| 3-Morpholinemethanol, 4-(phenylmethyl)-, hydrochloride | 916483-67-5 | / | / |
| (7S,9aS)-7-((Benzyloxy)methyl)octahydropyrazino[2,1-c][1,4]oxazine dioxalate salt | 1268364-46-0 | / | / |
| 2-(3,5-bis(trifluoroMethyl)phenyl)-2-Methyl propanoic acid | 289686-70-0 | / | / |
| ((7S)-octahydropyrazino[2,1-c][1,4]oxazin-7-yl)methanol | 929047-29-0 | / | / |
| 4-Boc-3-morpholinecarboxylic Acid | 212650-43-6 | / | / |
| 2-(3,5-bis-trifluoromethylphenyl)-2-methyl-propionyl chloride | 289686-69-7 | / | / |
Building toward Elinzanetant?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →